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A B S T R A C T
Multiple chemical sensitivities (MCS) is a medical condition associated with exposure to common chemical
pollutants. The aims of this study are to assess the prevalence of MCS, its overlaps with asthma and fragrance
sensitivity, and its health and societal effects in Australia. Data were collected in June 2016 using an on-line
survey with a representative national sample (N=1098) of adults (ages 18–65) in Australia. Results found that,
across the country, 6.5% report medically diagnosed MCS, 18.9% report chemical sensitivity (being unusually
sensitive to everyday chemicals and chemically formulated products), and 19.9% either or both. Among people
with MCS, 74.6% also have diagnosed asthma or an asthma-like condition, and 91.5% have fragrance sensitivity,
reporting health problems (such as migraine headaches) when exposed to fragranced consumer products (such as
air fresheners and cleaning supplies). In addition, among people with MCS, 77.5% are prevented from access to
places because of fragranced products, 52.1% lost workdays or a job in the past year due to fragranced product
exposure in the workplace, and 55.4% report health effects considered potentially disabling. Results indicate
that MCS is a widespread disease, affecting an estimated 1 million adult Australians, with chemical sensitivity
affecting another 2 million. Reducing chemical exposure to problematic sources, such as fragranced consumer
products, is critical to reduce adverse effects.
1. Introduction
People with multiple chemical sensitivities (MCS) experience ad-
verse health effects from exposure to common chemical pollutants,
often at low levels, from products such as pesticides, new carpet and
paint, renovation materials, diesel exhaust, cleaning supplies, scented
laundry products, air fresheners, and perfume (Ashford and Miller,
1998). Risks from exposure include a range of acute, chronic, and po-
tentially disabling health effects, including headaches, dizziness, sei-
zures, heart arrhythmia, gastrointestinal problems, breathing difficul-
ties, and asthma attacks (Steinemann, 2018; Ashford and Miller, 1998).
Prior studies found that people with MCS generally report a higher
incidence of fragrance sensitivity (adverse health effects from exposure
to fragranced consumer products) and of asthma (Steinemann, 2018;
Caress and Steinemann, 2009b).
While multiple chemical sensitivities (or sensitivity) is arguably the
most common term, the condition is also known as environmental ill-
ness (specific to chemical exposures), the petrochemical problem, or
toxicant induced loss of tolerance (Ashford and Miller, 1998; Miller and
Prihoda, 1999). Further, while progress has been made on elucidating
mechanisms of disease and biomarkers (e.g., Genuis, 2010; De Luca
et al., 2011; Belpomme et al., 2015), MCS still lacks a single
international case definition (MCS 1999, 1999; Ashford and Miller,
1998). People with MCS may not receive a distinct medical diagnosis,
but nonetheless manifest the condition of chemical sensitivity.
A hallmark of MCS is that it is typically both initiated and triggered
by chemical exposures. Sources commonly implicated in MCS (e.g.,
pesticides, solvents, new building materials, and fragranced consumer
products) are documented sources of air pollutants (McDonald et al.,
2018; Ott et al., 2007). People with MCS have been likened to human
canaries: they react earlier and more severely to pollutants, and at le-
vels far lower than the general population (Ashford and Miller, 1998).
Little is known about the prevalence of MCS in Australia. In one prior
study, a population-based survey of 4009 adults in South Australia in
2001–2002 found a prevalence of 15.9% of self-reported chemical sensi-
tivity and 1% medically diagnosed MCS (Fitzgerald, 2008). Chemical sen-
sitivity was investigated with the questions: “Is your health seriously af-
fected by exposure to any of the following (perfume, traffic pollution,
household chemicals, workplace chemicals)?” and “Do you consider your-
self especially sensitive to everyday chemicals found in household cleaning
products, perfumes, insect sprays, new carpets, fresh paints, etc.?”.
In other countries, a recent national study in the US (Steinemann,
2018) found a prevalence of 25.9% self-reported chemical sensitivity
and 12.8% medically diagnosed MCS. Prior US national prevalence
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studies, conducted in 2002–2003 and 2005–2006 (Caress and
Steinemann, 2005, 2009a), found respectively 11.1% and 11.6% self-
reported chemical sensitivity and 2.5% and 3.9% medically diagnosed
MCS. Thus, over the past decade, MCS prevalence has increased over
300% and chemical sensitivity over 200% in the US (Steinemann,
2018). Chemical sensitivity was investigated in these three national
studies using the question: “Compared to other people, do you consider
yourself allergic or unusually sensitive to everyday chemicals like those
in household cleaning products, paints, perfumes, detergents, insect
spray and things like that?” The fundamental question was developed
by the California Department of Health Services and used in their
survey of 4046 Californians (Kreutzer et al., 1999), and a modified
version was also used in the survey of South Australians (Fitzgerald,
2008). Using the Quick Environmental Exposure and Sensitivity In-
ventory (QEESI) criteria (Miller and Prihoda, 1999), a survey of 7245
adults in Japan (Azuma et al., 2015) and 2000 adults in Denmark
(Skovbjerg et al., 2012) estimated a prevalence of 7.5% and 8.2% re-
spectively of chemical intolerance.
The aims of this present study are three-fold: (1) to determine the
prevalence of medically diagnosed MCS and chemical sensitivity in
Australia, (2) to investigate its co-occurrence with asthma or an asthma-
like condition, and with fragrance sensitivity, and (3) to assess the
impact of exposure to fragranced consumer products on health and
quality of life for people with MCS. Results from this study point to
ways to reduce adverse effects and promote public health.
2. Methods
To assess the national prevalence and effects of MCS, an on-line
survey was conducted with a random sample of the Australian popu-
lation, representative of age, gender, and region (N=1098, 95% con-
fidence level, 3% margin of error), drawn from a large national panel
(over 200,000 people) held by Survey Sampling International. The
survey instrument was developed and tested over a two-year period
before full implementation in June 2016. Response rate was 93%, and
all responses were anonymous. (For details, see “Survey Methods” and
“Survey Data 2” as supplementary material.)
To promote comparability and consistency, the survey employed
questions from previous national and large-scale regional MCS pre-
valence studies (Steinemann, 2018; Caress and Steinemann, 2004,
2005, 2009a; Fitzgerald, 2008; Kreutzer et al., 1999). For medically
diagnosed MCS, the survey asked, “Has a doctor or health care pro-
fessional ever told you that you have multiple chemical sensitivities?”
For chemical sensitivity, the survey asked, “Compared to other people,
do you consider yourself allergic or unusually sensitive to everyday
chemicals like those in household cleaning products, paints, perfumes,
detergents, insect spray and things like that?”.
For asthma, the survey asked, “Has a doctor or health care profes-
sional ever told you that you have asthma or an asthma-like condition?”
and then further asked to specify whether asthma or an asthma-like
condition. (The term “asthmatic” will be used herein to include in-
dividuals with either asthma or an asthma-like condition or both.)
For fragrance sensitivity, the survey asked about exposure to dif-
ferent types of fragranced consumer products. An individual was con-
sidered to characterize fragrance sensitivity if they experienced one or
more types of health problems from one or more types of fragranced
products and exposure contexts (Steinemann, 2016). A “fragranced
consumer product” (or “fragranced product,” for brevity) is a chemi-
cally formulated product with the addition of a fragrance or scent
(Steinemann, 2015).
Fragranced product types were categorized as follows: air fresheners
and deodorizers, personal care products, cleaning supplies, laundry
products, household products, fragrance, and other. Specific exposure
contexts were as follows: air fresheners or deodorizers used in public
restrooms and other environments; scented laundry products coming
from a dryer vent; being in a room after it was cleaned with scented
cleaning products; being near someone wearing a fragranced product;
entering a business with the scent of fragranced products; fragranced
soap used in public restrooms; and ability to access environments that
used fragranced products. The survey also investigated effects of fra-
granced product exposure in the workplace, and preferences for fra-
grance-free environments and policies.
Health effects were categorized as follows: migraine headaches;
asthma attacks; neurological problems; respiratory problems; skin
problems; cognitive problems; mucosal symptoms; immune system
problems; gastrointestinal problems; cardiovascular problems; muscu-
loskeletal problems; and other. Data on fragranced product exposures
and effects were derived from a survey of the general population
(Steinemann, 2017), while the present study focuses specifically on
effects on the sub-populations of individuals with MCS or chemical
sensitivity. (See “Survey Data”)
3. Results
Across Australia, 6.5% report medically diagnosed MCS, 18.9% re-
port chemical sensitivity, and 19.9% either or both.
For co-occurrence with asthma: 74.6% of people with MCS are
asthmatic; that is, diagnosed with asthma (40.8%), an asthma-like
condition (47.9%), or both. Also, 56.5% of people with chemical sen-
sitivity are asthmatic; that is, diagnosed with asthma (32.9%), an
asthma-like condition (28.5%), or both. (See Table 1.)
For co-occurrence with fragrance sensitivity: 91.5% of people with
diagnosed MCS are also fragrance sensitive (Table 1), reporting one or
more types of health problems, such as respiratory difficulties (56.3%) and
migraine headaches (46.5%), when exposed to fragranced consumer
products (see Table 2). Also, 82.6% of people with chemical sensitivity are
also fragrance sensitive (Table 1), reporting one or more types of health
problems when exposed to fragranced products (see Table 2).
Specific fragranced product exposures that trigger health problems
for people with MCS include, but are not limited to, the following: air
fresheners and deodorizers (67.6%), scented laundry products coming
Table 1
Prevalence and co-occurrence of MCS and chemical sensitivity with asthma and fragrance
sensitivity.
Gen pop MCS diag ChemSens MCS/
ChemSens
Total (N) 1098 71 207 218
(% relative to general
population)
100.0% 6.5% 18.9% 19.9%











MCS diagnosed 71 71 60 71
6.5% 100.0% 29.0% 32.6%
Chemically sensitive 207 60 207 207




218 71 207 218
19.9% 100.0% 100.0% 100.0%
Asthma diagnosed 176 29 68 70
16.0% 40.8% 32.9% 32.1%
Asthma-like condition
diagnosed
151 34 59 64




313 53 117 123
28.5% 74.6% 56.5% 56.4%
Fragrance sensitive 362 65 171 179
33.0% 91.5% 82.6% 82.1%
Gen Pop= general population (including sub-populations of MCS and ChemSens).
MCS Diag=medically diagnosed with MCS.
ChemSens= self-reported chemical sensitivity.
MCS/ChemSens=medically diagnosed with MCS, or self-reported chemical sensitivity,
or both.
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from a dryer vent (49.3%), being in a room recently cleaned with
scented products (71.8%), being near someone wearing a fragranced
product (66.2%), and other types of fragranced consumer products
(78.9%) (see Table 2).
Importantly, for 55.4% of people with MCS, the severity of these
health problems was potentially disabling according to the criterion of
the Australian Disability Discrimination Act (DDA, 1992), as assessed
by a positive response to the question: “Do any of these health problems
mean a total or partial loss of bodily or mental functions, for you per-
sonally?” (See “Survey Data”)
Fragranced products also restrict access in society for people with
MCS: 64.8% are unable or reluctant to use public restrooms that have
an air freshener, deodorizer, or scented product; 57.7% are unable or
reluctant to wash hands in a public place if the soap is fragranced;
64.8% enter a business but then leave as quickly as possible due to a
fragranced product; and 77.5% have been prevented from going
someplace because a fragranced product would make them sick.
Significantly, 52.1% of those with MCS lost workdays or a job in the
past year due to illness from fragranced product exposure in the
workplace, 77.5% would support a fragrance-free policy in the work-
place, and 80.3% would prefer that health care facilities and profes-
sionals were fragrance-free.
Demographic proportions of diagnosed MCS are 47.9% male and
52.1% female, compared with the general population of 49.5% male
and 50.5% female. Thus, diagnosed MCS has a slight female bias
(+1.6%). Relative to gender and age, the highest bias (percentage MCS
greater than general population) is Male 25–34 (+8.4%).
4. Discussion
Results of this study indicate that MCS is widespread in the
Australian population, affecting an estimated 1 million adults, with
chemical sensitivity affecting another 2 million adults (ABS, 2016).
Among people diagnosed with MCS, 74.6% report being also diag-
nosed with asthma or an asthma-like condition. People with MCS are
proportionally more likely to be asthmatic than people without MCS
(prevalence odds ratio 8.7; 95% confidence interval 5.0–15.1).
In addition, among people diagnosed with MCS, 91.5% report fra-
grance sensitivity. People with MCS are proportionally more likely to be
fragrance sensitive than people without MCS (prevalence odds ratio
26.6; 95% confidence interval 11.4–62.1).
Fragranced consumer products can trigger severe and potentially
disabling health effects in a majority of people with MCS. Consequently,
people with MCS are prevented from accessing restrooms, businesses,
workplaces, and public places due to risks of adverse health effects from
fragranced consumer products. A majority of people with MCS have lost
workdays or a job, in the past year, due to exposure to fragranced
products in the workplace.
Table 2
Health problems (frequency and type) from exposure to fragranced consumer products.
Gen pop MCS diag ChemSens MCS/ChemSens
Total (N) 1098 71 207 218
(% relative to General Population) 100.0% 6.5% 18.9% 19.9%
(N) (N) (N) (N)
(% of column total) (% of column total) (% of column total) (% of column total)
Fragrance sensitive 362 65 171 179
33.0% 91.5% 82.6% 82.1%
Health problems from exposure to
Air fresheners or deodorizers 180 48 106 110
16.4% 67.6% 51.2% 50.5%
Scented laundry products from a dryer vent 67 35 48 52
6.1% 49.3% 23.2% 23.9%
Room cleaned with scented products 168 51 115 119
15.3% 71.8% 55.6% 54.6%
Someone wearing a fragranced product 213 47 115 117
19.4% 66.2% 55.6% 53.7%
Any type of fragranced consumer product 223 56 132 136
20.3% 78.9% 63.8% 62.4%
Type of health problem
*Migraine headaches 110 33 64 68
10.0% 46.5% 30.9% 31.2%
*Asthma attacks 83 28 52 54
7.6% 39.4% 25.1% 24.8%
*Neurological problems (e.g., dizziness, seizures, head pain, fainting, loss of
coordination)
49 19 32 34
4.5% 26.8% 15.5% 15.6%
*Respiratory problems (e.g., difficulty breathing, coughing, shortness of breath) 183 40 98 102
16.7% 56.3% 47.3% 46.8%
*Skin problems (e.g., rashes, hives, red skin, tingling skin, dermatitis) 104 36 67 71
9.5% 50.7% 32.4% 32.6%
*Cognitive problems (e.g., difficulties thinking, concentrating, or remembering) 45 27 32 36
4.1% 38.0% 15.5% 16.5%
*Mucosal symptoms (e.g., watery or red eyes, nasal congestion, sneezing) 154 34 87 90
14.0% 47.9% 42.0% 41.3%
*Immune system problems (e.g., swollen lymph glands, fever, fatigue) 36 20 23 25
3.3% 28.2% 11.1% 11.5%
*Gastrointestinal problems (e.g., nausea, bloating, cramping, diarrhea) 36 14 22 23
3.3% 19.7% 10.6% 10.6%
*Cardiovascular problems (e.g., fast or irregular heartbeat, jitteriness, chest discomfort) 33 14 20 21
3.0% 19.7% 9.7% 9.6%
*Musculoskeletal problems (e.g., muscle or joint pain, cramps, weakness) 29 15 17 19
2.6% 21.1% 8.2% 8.7%
*Other 21 – 4 4
1.9% – 1.9% 1.8%
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In light of these results, a logical and prudent step would be to
implement fragrance-free policies in workplaces and other environ-
ments, which could improve access for people with MCS and reduce
potential health risks and liability. Even among the general population,
most Australians would support fragrance-free workplaces, health care
facilities, and health care professionals (Steinemann, 2017).
Study strengths include the following: (a) the sample population is
statistically representative of age, gender, and region in Australia; (b)
the 1098 respondents were randomly recruited from a large web-based
panel, developed from multiple sources to reflect population char-
acteristics; and (c) the survey used questions from a large national study
in the US previously conducted and published (Steinemann, 2018).
Study limitations include the following: (a) only adults (ages 18–65)
were surveyed, which excludes data from other age groups; (b) the
survey relied on self-reported data, although a standard and widely
accepted approach for epidemiological research; (c) the cross-sectional
design limits the investigation of temporal associations between ex-
posures and effects; and (d) MCS and chemical sensitivity lack standard
diagnostic criteria, although the survey replicated questions from prior
large-scale studies to promote consistency and comparability.
5. Conclusion
MCS is a serious and potentially disabling health condition and is
exacerbated by exposure to common chemically formulated products.
Reducing exposure to problematic sources is critical for both primary
and secondary prevention: to prevent more people from acquiring MCS,
and to reduce the frequency and severity of adverse health and societal
effects among an estimated 3 million Australians who already have
chemical sensitivity or MCS.
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